Skip to content

Effect of esketamine and sufentanil on postoperative gastrointestinal function recovery in patients undergoing laparoscopic radical resection of colorectal cancer

Effect of esketamine and sufentanil on postoperative gastrointestinal function recovery in patients undergoing laparoscopic radical resection of colorectal cancer

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200064753
Enrollment
Unknown
Registered
2022-10-17
Start date
2022-11-01
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Recovery of gastrointestinal function after colorectal cancer surgery

Interventions

The experimental group:esketamine

Sponsors

Affiliated Hospital of Guangdong Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Preoperative clinical diagnosis of colorectal cancer patients; 2. 18 years old<=age<=75 years; 3. Planned laparoscopic radical resection of colorectal cancer under general anesthesia with tracheal intubation; 4. The preoperative ASA anesthesia score is I to III; 5. Hematology, liver and kidney functions are normal, and cardiopulmonary function tests indicate tolerability for surgery; 6. No preoperative radiotherapy or chemotherapy was received; 7. Able to understand and comply with the study, and sign an informed consent form to participate in this study.

Exclusion criteria

Exclusion criteria: 1. Preoperative intestinal diseases (such as ulcerative colitis, Krohn's disease and irritable bowel syndrome); 2. Patients at serious risk of elevated intracranial pressure; 3. Patients with poor control or untreated hypertension (resting blood pressure = 180/100mg); 4. Untreated or insufficiently treated patients with hyperthyroidism; 5. Patients with liver and kidney dysfunction; 6. Patients with allergies to anesthetic drugs (Esketamine); 7. Participate in other clinical studies within 3 months before surgery; 8. Failure to sign informed consent.

Design outcomes

Primary

MeasureTime frame
Time of first postoperative anal exhaust;

Secondary

MeasureTime frame
Plasma C-reactive protein;Incidence of adverse reactions (nausea, vomiting, dizziness);Postoperative analgesia;

Countries

China

Contacts

Public ContactCao Dianqing

Affiliated Hospital of Guangdong Medical University

346013921@qq.com+86 13600386634

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026